Cargando…
Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection
BACKGROUND: The combination of boceprevir or telaprevir with peginterferon-alfa and ribavirin for the treatment of patients infected with HCV genotype 1 has led to significantly increased rates of sustained virological response (SVR) in phase III trials. There is only limited data regarding the safe...
Autores principales: | Wehmeyer, Malte H, Eißing, Friederike, Jordan, Sabine, Röder, Claudia, Hennigs, Annette, Degen, Olaf, Hüfner, Anja, Hertling, Sandra, Schmiedel, Stefan, Sterneck, Martina, van Lunzen, Jan, Lohse, Ansgar W, zur Wiesch, Julian Schulze, Lüth, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102246/ https://www.ncbi.nlm.nih.gov/pubmed/24884400 http://dx.doi.org/10.1186/1471-230X-14-87 |
Ejemplares similares
-
German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
por: Beisel, Claudia, et al.
Publicado: (2014) -
Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients
por: Brehm, Thomas Theo, et al.
Publicado: (2019) -
Frequent detection of functional hyposplenism via assessment of pitted erythrocytes in patients with advanced liver cirrhosis
por: Wehmeyer, Malte H., et al.
Publicado: (2022) -
Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity
por: Drolz, Andreas, et al.
Publicado: (2021) -
Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)
por: Schäfer, Guido, et al.
Publicado: (2019)